Iqgen-X Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.13 Cr
as on 16-11-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.28 Cr
as on 16-11-2024
- Revenue -13.64%
(FY 2023)
- Profit 86.35%
(FY 2023)
- Ebitda 373.39%
(FY 2023)
- Net Worth 5.17%
(FY 2023)
- Total Assets -3.00%
(FY 2023)
About Iqgen-X Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.13 Cr.
The company currently has active open charges totaling ₹2.28 Cr.
Parizad Elchidana, Karan Singh, Madhu Hariharan, and Three other members serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC286716
- Company No.
286716
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Oct 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNavi Mumbai, Maharashtra
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Iqgen-X Pharma?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parizad Elchidana  | Additional Director | 30-Sep-2021 | Current |
Karan Singh  | Additional Director | 16-Oct-2020 | Current |
Madhu Hariharan  | Director | 01-Apr-2017 | Current |
| Yatendra Kumar | Director | 01-Apr-2017 | Current |
| Mandar Kodgule | Director | 01-Apr-2017 | Current |
| Yogita Kodgule | Director | 01-Apr-2017 | Current |
Financial Performance and Corporate Structure Insights of Iqgen-X Pharma.
Iqgen-X Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.64% decrease. The company also saw a substantial improvement in profitability, with a 86.35% increase in profit. The company's net worth moved up by a moderate rise of 5.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Iqgen-X Pharma?
In 2023, Iqgen-X Pharma had a promoter holding of 40.80% and a public holding of 59.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 28 Jul 2020 | ₹2.80 M | Open |
Canara Bank Creation Date: 25 Sep 2017 | ₹2.00 Cr | Open |
How Many Employees Work at Iqgen-X Pharma?
Iqgen-X Pharma has a workforce of 34 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iqgen-X Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iqgen-X Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
